Beijing 's BeiGene announced a $310 million agreement for China/Asia rights to an mRNA treatment developed by Strand Therapeutics for solid tumor cancers. Strand, a Cambridge , MA biotech, focuses on programmable mRNA therapies for cancer and other diseases. BeiGene made a $5 million upfront equity investment in Strand for an option to two Strand immuno-oncology programs using Strand’s intratumoral or systemic delivery mechanism, saying Strand 's candidates are "cutting-edge novel programs." Strand also received an additional $10 million equity investment from an unnamed party. More details.... Stock Symbols: (NSDQ: BGNE; HK: 06160) Share this with colleagues: // //